Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Chemomab Therapeutics Ltd. Sponsored ADR (CMMB : NSDQ)

• Company Description    Chemomab Ltd. is a clinical-stage biotech company. It focuses on the discovery and development of innovative therapeutics for fibrosis-related diseases with high unmet need. The company's product pipeline includes CM-101. Chemomab Ltd., formerly known as Anchiano Therapeutics Ltd., is based in TEL-AVIV, Israel. Number of Employees: 16

• Price / Volume Information    Yesterday's Closing Price: $3.39 Daily Weekly Monthly 20 Day Moving Average: 284,935 shares Shares Outstanding: 5.17 (millions) Market Capitalization: $17.54 (millions) Beta: 0.57 52 Week High: $9.84 52 Week Low: $2.39 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 30.39% 28.87% 12 Week -22.25% -26.45% Year To Date -53.18% -59.11%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL KIRYAT ATIDIM BUILDING 7 - TEL AVIV,L3 6158002 ISR ph: 972-77-331-0156 fax: - ir@chemomab.com http://www.chemomab.com

• General Corporate Information    Officers Adi Mor - Chief Executive Officer; Chief Scientific Officer Nissim Darvish - Chairman Sigal Fattal - Chief Financial Officer Alan Moses - Director Claude Nicaise - Director Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 16385C203 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 06/01/25 Next Expected EPS Date: 11/13/25 Share - Related Items Shares Outstanding: 5.17 Most Recent Split Date: 8.00 (0.25:1) Beta: 0.57 Market Capitalization: $17.54 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.20 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-0.60 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 1.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 11/13/25

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 1.65 Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: 65.38% vs. Previous Quarter: 35.71% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 09/30/25 - - 06/30/25 - -94.71 03/31/25 - -106.70 ROA 09/30/25 - - 06/30/25 - -76.53 03/31/25 - -82.18 Current Ratio 09/30/25 - - 06/30/25 - 7.42 03/31/25 - 5.33 Quick Ratio 09/30/25 - - 06/30/25 - 7.42 03/31/25 - 5.33 Operating Margin 09/30/25 - - 06/30/25 - - 03/31/25 - - Net Margin 09/30/25 - - 06/30/25 - - 03/31/25 - - Pre-Tax Margin 09/30/25 - - 06/30/25 - - 03/31/25 - - Book Value 09/30/25 - - 06/30/25 - 2.06 03/31/25 - 2.20 Inventory Turnover 09/30/25 - - 06/30/25 - - 03/31/25 - - Debt-to-Equity 09/30/25 - - 06/30/25 - 0.00 03/31/25 - 0.00 Debt-to-Capital 09/30/25 - - 06/30/25 - 0.00 03/31/25 - 0.00

Powered by Zacks Investment Research ©